KKM Global Group Announces Strategic Term Sheet with Visionary Oncology and Integrated Molecular Solutions

FOR IMMEDIATE RELEASE December 4, 2024

KKM Global Group Announces Strategic Term Sheet with Visionary Oncology and Integrated Molecular Solutions

The Villages, FL — KKM Global Group, LLC through its wholly owned subsidiary Visionary Oncology (VO), is pleased to announce the execution of a strategic term sheet with Integrated Molecular Solutions, LLC (IMS). This agreement marks a pivotal step toward advancing the availability and innovation of radiotherapy and molecular imaging solutions globally.

IMS, renowned for its expertise in oncology and molecular imaging operations, has committed to acquiring a 49% equity stake in Visionary Oncology. This partnership will bring together IMS's clinical insights and technical expertise with KKM’s leadership in radiotherapy project development to deliver state-of-the-art solutions to healthcare providers worldwide.

Key highlights of the agreement include:

• Collaborative Expertise: IMS will provide intellectual property, know-how, and operational management services to support VO’s radiotherapy, oncology, and theranostics projects.

• Innovative Projects: The partnership will focus on deploying advanced radiotherapy and molecular imaging systems, including cutting-edge radiosurgery technology from Akesis, a leading provider of integrated radiotherapy and radiosurgery systems.

• Strategic Leadership: A newly established five-member board of directors will oversee the collaboration, ensuring alignment with shared goals and sustainable growth.

"IMS's vision aligns perfectly with our goal of expanding access to high-quality care," said Jeff Reichman, Chief Operating Officer of KKM Global Group. "Our partnership with IMS and the integration of Akesis technology place us in a strong position to address the evolving needs of global oncology care."

Leonard A. Farber, MD, Chief Medical Officer of IMS, added, "This partnership represents a significant leap forward in our mission to revolutionize oncology care. By combining our expertise with Visionary Oncology and leveraging Akesis's state-of-the-art technology, we are poised to deliver groundbreaking solutions that improve outcomes for patients worldwide."

This strategic partnership underscores the commitment of IMS and VO to jointly develop innovative radiotherapy solutions while fostering growth in the healthcare market.

For more information, please contact:

Jeff ReichmanChief Operating OfficerKKM Global GroupEmail: jreichman@kkmhealthcare.com

Leonard A. Farber, MDChief Medical OfficerIntegrated Molecular Solutions, LLCEmail: lfarbermd@integratedmolecular.net

About KKM Global Group KKM Global Group is a leader in selling, financing, and developing advanced radiotherapy equipment and projects. Through its subsidiary Visionary Oncology, KKM is committed to enhancing radiotherapy services worldwide.

About Integrated Molecular Solutions, LLC Integrated Molecular Solutions specializes in innovative oncology and molecular imaging solutions, combining clinical expertise with cutting-edge technology to deliver superior healthcare outcomes.